Diane Phillips
Internal Medicine · Dallas, TXNPI 1649393463
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 167 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 15.5% — the pattern of someone who eats at a lot of different presentations.
Across 167 payments — averaging $21.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$548
- Amgen$443
- Novo Nordisk$273
- Takeda Pharmaceuticals U.S.A., Inc.$254
- GSK$249
- Bausch Health US, LLC$221
- plus $2K from 20 others
What the payments were for
- Food & beverage$3,531100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 15 | $548 |
| Amgen | 15 | $443 |
| Novo Nordisk | 10 | $273 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $254 |
| GSK | 13 | $249 |
| Bausch Health US, LLC | 13 | $221 |
| Eisai Inc. | 13 | $215 |
| Supernus Pharmaceuticals, Inc. | 6 | $195 |
| AbbVie | 11 | $163 |
| Pfizer | 9 | $158 |
| Currax Pharmaceuticals LLC | 10 | $144 |
| Lilly USA, LLC | 9 | $117 |
| Otsuka America Pharmaceutical, Inc. | 6 | $103 |
| Idorsia Pharmaceuticals US Inc | 4 | $61 |
| Genentech USA, Inc. | 3 | $54 |
| Adlon Therapeutics L.p. | 3 | $51 |
| Cleerly, Inc. | 1 | $42 |
| Biohaven Pharmaceuticals, Inc. | 2 | $39 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $36 |
| Arbor Pharmaceuticals, Inc. | 2 | $31 |
| Shire North American Group Inc | 2 | $28 |
| Alfasigma USA, Inc. | 1 | $27 |
| Millicent US Inc | 1 | $22 |
| Azurity Pharmaceuticals, Inc. | 1 | $21 |
| Dermira, Inc. | 1 | $20 |
| Paratek Pharmaceuticals, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,531 in reported general payments places this provider in the 85th percentile of 7,675 internal medicine providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 53 | $47,150 |
| OzempicSemaglutide | 27 | $23,601 |
| MounjaroTirzepatide | 11 | $11,568 |
| XareltoRivaroxaban | 13 | $11,472 |
| SynthroidLevothyroxine Sodium | 137 | $8,129 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $5,315 |
| Ibandronate Sodium | 82 | $3,413 |
| PremarinEstrogens, Conjugated | 12 | $2,786 |
| Estradiol | 31 | $2,410 |
| ValacyclovirValacyclovir Hcl | 13 | $1,269 |
| Ezetimibe | 60 | $999 |
| Trazodone Hcl | 57 | $975 |
| Dutasteride | 24 | $967 |
| Bupropion XlBupropion Hcl | 56 | $963 |
| Atorvastatin Calcium | 114 | $928 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $548 | $47,15053 claims |
| Novo NordiskOzempic | $273 | $23,60127 claims |
| Lilly USA, LLCMounjaro | $117 | $11,56811 claims |
| AbbVieSynthroid | $163 | $8,129137 claims |
| GSKBreo Ellipta | $249 | $5,31511 claims |
| PfizerPremarin | $158 | $2,78612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Dallas
- Marc TribbleDallas$693K
- Gary SinclairDallas$599K
- Han SchmidlyDallas$465K
- Athica VatanapradithDallas$164K
- Nicholaos BellosDallas$113K
- Steven HeldDallas$65K
- Amit VermaDallas$53K
- Spencer BerthelsenSugar Land$891K
- Hameed AliTemple$773K
- Mohammed Al-NajjarEl Paso$586K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.